MM-111 Posters

Preclinical Posters

 

AACR 2013

MM-111, a Bi-specific HER2 and HER3 Antibody, Synergistically Combines with Trastuzumab and Paclitaxel in Preclinical Models of Gastric Cancer (presentation)

ASCO GI 2013

MM-111, a bi-specific ErbB2/ ErbB3 antibody, demonstrates pre-clinical activity in previously treated ErbB2 positive gastric and gastroesophageal junction cancers

AACR 2012

MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth

Targeting ErbB3-Addicted Cancers Across the ErbB2 Spectrum

Combating adaptive ErbB3-mediated resistance to ErbB2 inhibitors: In Silico optimization of MM-111 and lapatinib dosing regimens

AACR/EORTC 2011

Optimization of MM-111 and lapatinib dosing regimens using mathematical modeling and quantitative biology

AACR 2011

Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as a treatment strategy in models of ER+/HER2+ breast cancer

MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells

Clinical Posters

 

ESMO 2012 

A Phase 1 Pharmacologic Study of MM-111, a Bispecific HER2/HER3 Antibody Fusion Protein, in Combination with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors

San Antonio Breast Cancer Symposium 2010 

MM-111 – A novel bispecific antibody targeting HER-2/HER-3 heterodimer: Safety and tolerability in a first-inhuman Phase 1/2 study in patients with refractory HER2+ cancers

 

Related Content

MM-111 Gastric/GEJ Cancer